CJC-1295 DAC – (446262-90-4)

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) developed by ConjuChem Biotechnologies.

It is a modified form of GHRH (1-29) with improved pharmacokinetics, particularly in terms of half-life. CJC-1295 may significantly increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.

A single injection could elevate plasma GH levels by 2- to 10-fold for up to 6 days and IGF-1 levels by 0.5- to 3-fold for 9 to 11 days. The drug has an estimated half-life of 6 to 8 days in humans due to the addition of a drug affinity complex (DAC) that binds to albumin, prolonging its presence in the bloodstream.

CJC-1295 is primarily used for its potential to stimulate GH release from the pituitary gland. It was investigated for treating lipodystrophy and growth hormone deficiency but was discontinued after a trial subject’s death.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) developed by ConjuChem Biotechnologies.

It is a modified form of GHRH (1-29) with improved pharmacokinetics, particularly in terms of half-life. CJC-1295 may significantly increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.

A single injection could elevate plasma GH levels by 2- to 10-fold for up to 6 days and IGF-1 levels by 0.5- to 3-fold for 9 to 11 days. The drug has an estimated half-life of 6 to 8 days in humans due to the addition of a drug affinity complex (DAC) that binds to albumin, prolonging its presence in the bloodstream.

CJC-1295 is primarily used for its potential to stimulate GH release from the pituitary gland. It was investigated for treating lipodystrophy and growth hormone deficiency but was discontinued after a trial subject’s death.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/CJC-1295
https://pubchem.ncbi.nlm.nih.gov/compound/91976842
https://www.medkoo.com/products/43244
https://www.corepeptides.com/cjc-1295-dac-peptide-and-hormonal-regulation/

CAS	446262-90-4
Molecular Weight	3367.9
Molecular Formula	C152H252N44O42
SMILES	CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC3=CC=C(C=C3)O)N

Products

Consulting & Services

Check Out Our Research And Updates

CJC-1295 DAC – (446262-90-4)

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) developed by ConjuChem Biotechnologies.

It is a modified form of GHRH (1-29) with improved pharmacokinetics, particularly in terms of half-life. CJC-1295 may significantly increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.

CJC-1295 is primarily used for its potential to stimulate GH release from the pituitary gland. It was investigated for treating lipodystrophy and growth hormone deficiency but was discontinued after a trial subject’s death.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/CJC-1295
https://pubchem.ncbi.nlm.nih.gov/compound/91976842
https://www.medkoo.com/products/43244
https://www.corepeptides.com/cjc-1295-dac-peptide-and-hormonal-regulation/

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

CJC-1295 DAC – (446262-90-4)

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) developed by ConjuChem Biotechnologies.

It is a modified form of GHRH (1-29) with improved pharmacokinetics, particularly in terms of half-life. CJC-1295 may significantly increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.

CJC-1295 is primarily used for its potential to stimulate GH release from the pituitary gland. It was investigated for treating lipodystrophy and growth hormone deficiency but was discontinued after a trial subject’s death.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/CJC-1295 https://pubchem.ncbi.nlm.nih.gov/compound/91976842 https://www.medkoo.com/products/43244 https://www.corepeptides.com/cjc-1295-dac-peptide-and-hormonal-regulation/

Related products

Quick Contact

https://en.wikipedia.org/wiki/CJC-1295
https://pubchem.ncbi.nlm.nih.gov/compound/91976842
https://www.medkoo.com/products/43244
https://www.corepeptides.com/cjc-1295-dac-peptide-and-hormonal-regulation/